Back to top

crispr: Archive

Zacks Equity Research

Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?

On Vertex Pharmaceuticals' (VRTX) Q2 earnings call, investors are most likely to focus on the sales performance of its cystic fibrosis (CF) medicines and updates on its non-CF pipeline candidates.

VRTXNegative Net Change ADCTPositive Net Change IONSNegative Net Change CRSPPositive Net Change

Zacks Equity Research

CRISPR (CRSP) to Report Q2 Earnings: What's in the Cards?

On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look for updates on its pipeline candidates, especially its lead candidate exa-cel.

AZNPositive Net Change VRTXNegative Net Change BAYRYPositive Net Change CRSPPositive Net Change

Neena Mishra

Should You Buy Beaten-Down Biotech Stocks & ETFs?

We highlight 4 ETFs that have started rebounding after a brutal sell-off

AMGNNegative Net Change GILDNegative Net Change VRTXNegative Net Change IBBPositive Net Change TDOCPositive Net Change XBIPositive Net Change CRSPPositive Net Change ARKGPositive Net Change IBBQPositive Net Change

Zacks Equity Research

CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs

While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.

ALKSPositive Net Change VRTXNegative Net Change CRSPPositive Net Change SESNPositive Net Change

Zacks Equity Research

CRISPR Therapeutics (CRSP) Q1 Earnings & Sales Miss Estimates

CRISPR Therapeutics (CRSP) reports wider-than-expected Q1 loss. Revenues miss estimates.

ALKSPositive Net Change VRTXNegative Net Change CRSPPositive Net Change

Zacks Equity Research

Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat

Intellia Therapeutics (NTLA) posts wider-than-expected Q1 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.

REGNNegative Net Change ALKSPositive Net Change FOLDPositive Net Change NTLAPositive Net Change